Routine Generation of Powder Samples from HPLC Fractions
Genevac reports that its HT Series II Evaporator using the Fast Lyophilisation, or LyoSpeed process is enabling a growing number of pharmaceutical labs to routinely dry HPLC fraction samples to a powder form, such that the samples can then be accurately weighed, easily sub-sampled and redissolved.
When working with certain HPLC solvents, such as water and acetonitrile, a fully dried result can be hard to achieve due to interactions with the dissolved sample — esulting in the formation of a gum or oil.
To provide a rapid, high-throughput alternative to freeze drying HPLC purification fractions — Genevac developed its proprietary fast lyophilisation (LyoSpeed) methodology for use on the HT Series II Evaporators. Although LyoSpeed works well for most hydrophilic samples, difficulties may arise where the sample cannot dissolve in only water. In such situations, when the organic solvent is removed, the sample crashes out forming an oil which until now required further processing to achieve the desired dry powder form. For such samples and to improve LyoSpeed results generally — Genevac developed the SuperCool 75 which chills to -75 ºC and operates at higher power than any other commercially available condenser.
Customer trials have shown that the Genevac HT Series II Evaporator/SuperCool 75 combination produces powdered lyophilisation samples using the LyoSpeed methodology from even the most difficult to handle samples with a success rate as high as 95%
For further information please visit www.genevac.com/en/
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...